Key result
Marathon running significantly increased sST2 concentrations in all participants from a median of 34 ng/mL at baseline to 70 ng/mL at the finish, with faster runners exhibiting higher levels.
Why the study?
Does running a marathon increase soluble ST2 (sST2) concentrations in moderately to highly trained runners?
Cross-Sectional (n=82)
Does running a marathon increase soluble ST2 (sST2) concentrations in moderately to highly trained runners?
Marathon running induces significant acute increases in the cardiac biomarker sST2, with higher concentrations observed in faster runners, suggesting complex hemodynamic or inflammatory responses to extreme endurance exercise.
Answers are grounded in this paper and cite their sources.
Post-marathon sST2 rises warrant cautious biomarker interpretation; leaves open prognostic implications for endurance athletes.
PURPOSE: Previous studies have suggested that extreme endurance exercise may induce cardiac microdamage that could lead to subsequent myocardial fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a cardiac biomarker for assessment of myocardial fibrosis, inflammation, and strain. We evaluated baseline and exercise-induced sST2 concentrations in a heterogeneous cohort of marathon runners to identify predictors for sST2 concentrations. METHODS: Ninety-two runners supplied demographic data, health status, physical activity levels, and marathon experience. Before (baseline) and immediately after (finish) the marathon, blood was collected for analysis of sST2 and cardiac troponin I (cTnI). RESULTS: Eighty-two participants (45 ± 8 yr, 79% male) finished the race in 227 ± 28 min at 92% (88%-94%) of their predicted maximum heart rate (exercise intensity). sST2 concentrations increased in all runners, from 34 (25-46) ng·mL to 70 (53-87) ng·mL (P < 0.001), and cTnI increased from 9 (5-21) ng·L to 60 (34-102) ng·L (P < 0.001). sST2 concentrations were higher in the fastest marathon runners. Sex and marathon personal best time were associated with baseline sST2 (R = 0.27); baseline sST2, weight loss, and exercise intensity during marathon were associated with finish sST2 (R = 0.54); baseline sST2, height, sex, and weekly training hours were associated with the exercise-induced increase in sST2 (R = 0.47). We observed no association between sST2 and cTnI concentrations. CONCLUSION: An exercise-induced increase in sST2 was observed in all marathon runners with sST2 concentrations exceeding cutoff values both at baseline (48%) and finish (94%). Faster runners had higher sST2 concentrations. Our data suggest complex variables determine sST2 concentrations in marathon runners.
No takes yet. Share an insight, caveat, or question.
Aengevaeren et al. (2018) conducted a cross-sectional in Healthy marathon runners (n=82). Marathon running vs. Baseline (pre-marathon) was evaluated on sST2 concentrations (ng/mL) (p=<0.001). Marathon running significantly increased sST2 concentrations in all participants from a median of 34 ng/mL at baseline to 70 ng/mL at the finish, with faster runners exhibiting higher levels.
Synapse has enriched 10 related papers. Consider them for comparative context: